James Tcheng, MD

Dr. James Tcheng is an Associate Professor of Medicine at the Duke Clinical Research Institute and the Duke University Health System in Durham, North Carolina, USA. He attended medical school at Johns Hopkins University and completed internship and residency at Barnes Hospital in St. Louis, MO. He attended Duke University for cardiology fellowship, and was appointed to the faculty of Duke in 1988.

Dr. Tcheng is a practicing interventional cardiologist who has performed over 2,500 therapeutic angioplasty procedures. He has expertise in the study and application of antiplatelet and antithrombin therapeutics, design and conduct of clinical trials, engineering of coronary angioplasty systems, and computer database and networking technologies. His research interests have focused on several areas, including direct angioplasty and stenting in acute myocardial infarction, excimer laser angioplasty in cardiovascular disease, the platelet glycoprotein IIb/IIIa inhibitors in coronary intervention and the acute coronary syndromes, and the newer antithrombin agents in vascular disease. He has been the principal investigator or co-principal investigator of a number of major clinical trials, including the PAR and CADILLAC trials of direct angioplasty during acute myocardial infarction, the EPIC, EPILOG, PROLOG, EPISTENT, and R3 trials of the platelet inhibitor abciximab (ReoPro), the IMPACT, IMPACT II, PRIDE, and ESPRIT trials of eptifibatide (Integrilin), and the LARS study of the excimer laser in the treatment of in-stent restenosis.